|
JPH02214856A
(ja)
|
1989-02-16 |
1990-08-27 |
Konica Corp |
ハロゲン化銀カラー写真感光材料
|
|
US20010056114A1
(en)
|
2000-11-01 |
2001-12-27 |
D'amato Robert |
Methods for the inhibition of angiogenesis with 3-amino thalidomide
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
HU228769B1
(en)
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
ATE493983T1
(de)
|
1996-11-05 |
2011-01-15 |
Childrens Medical Center |
Thalidomide und dexamethason für die behandlung von tumors
|
|
US6093737A
(en)
|
1996-12-30 |
2000-07-25 |
Merck & Co., Inc. |
Inhibitors of farnesyl-protein transferase
|
|
US5874448A
(en)
|
1997-11-18 |
1999-02-23 |
Celgene Corporation |
Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels
|
|
US5955476A
(en)
|
1997-11-18 |
1999-09-21 |
Celgene Corporation |
Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels
|
|
TR200101502T2
(tr)
*
|
1998-03-16 |
2002-06-21 |
Celgene Corporation |
2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
|
|
JP2000159761A
(ja)
|
1998-11-30 |
2000-06-13 |
Yoshio Takeuchi |
フルオロサリドマイド
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
US6388090B2
(en)
|
2000-01-14 |
2002-05-14 |
Orion Corporation |
Imidazole derivatives
|
|
US6458810B1
(en)
|
2000-11-14 |
2002-10-01 |
George Muller |
Pharmaceutically active isoindoline derivatives
|
|
US7091353B2
(en)
|
2000-12-27 |
2006-08-15 |
Celgene Corporation |
Isoindole-imide compounds, compositions, and uses thereof
|
|
US20030045552A1
(en)
*
|
2000-12-27 |
2003-03-06 |
Robarge Michael J. |
Isoindole-imide compounds, compositions, and uses thereof
|
|
ES2172474B1
(es)
|
2001-03-01 |
2004-01-16 |
Fundacion Universitaria San Pa |
Derivados de glutarimida como agentes terapeuticos.
|
|
NZ531294A
(en)
|
2001-08-06 |
2005-11-25 |
Childrens Medical Center |
Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs
|
|
TWI298724B
(en)
|
2001-11-15 |
2008-07-11 |
Celgene Corp |
Pharmaceutically active isoindoline derivatives
|
|
EP1336602A1
(en)
|
2002-02-13 |
2003-08-20 |
Giovanni Scaramuzzino |
Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases
|
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
CN1164586C
(zh)
|
2002-10-28 |
2004-09-01 |
中国科学院长春应用化学研究所 |
沙利度胺及其衍生物的制备方法
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
CH696542A5
(de)
|
2003-07-09 |
2007-07-31 |
Siegfried Ltd |
Verfahren zur Herstellung von substituierten 2,6-Dioxopiperidin-3-yl-Verbindungen.
|
|
CN100398534C
(zh)
|
2003-09-15 |
2008-07-02 |
天津和美生物技术有限公司 |
合成酞胺哌啶酮及其衍生物的方法
|
|
US7973057B2
(en)
|
2003-09-17 |
2011-07-05 |
The United States Of America As Represented By The Department Of Health And Human Services |
Thalidomide analogs
|
|
US7612096B2
(en)
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
CA2560221C
(en)
|
2004-03-22 |
2010-12-07 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
JP2005336157A
(ja)
|
2004-04-30 |
2005-12-08 |
Arigen Inc |
光学活性サリドマイドおよびその誘導体の製造法
|
|
EP1797068B1
(en)
|
2004-09-03 |
2013-10-09 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
|
|
CN101098694A
(zh)
|
2004-11-12 |
2008-01-02 |
细胞基因公司 |
使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物
|
|
MX2007010037A
(es)
|
2005-02-18 |
2008-02-15 |
Novartis Vaccines & Diagnostic |
Agentes antiangiogenicos con aldesleucina.
|
|
CN100383139C
(zh)
|
2005-04-07 |
2008-04-23 |
天津和美生物技术有限公司 |
可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
UA91560C2
(ru)
|
2005-08-31 |
2010-08-10 |
Селджин Корпорэйшн |
Соединения ряда изоиндолимидов, их композиция и применение
|
|
CA2633980A1
(en)
|
2005-12-29 |
2007-07-12 |
Anthrogenesis Corporation |
Improved composition for collecting and preserving placental stem cells and methods of using the composition
|
|
US20080064876A1
(en)
|
2006-05-16 |
2008-03-13 |
Muller George W |
Process for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CL2007002513A1
(es)
*
|
2006-08-30 |
2008-04-04 |
Celgene Corp Soc Organizada Ba |
Compuestos derivados de isoindolina sustituidos, compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento y prevencion de enfermedades tales como cancer, dolor, degeneracion macular, entre otras.
|
|
JP2009001528A
(ja)
|
2007-06-22 |
2009-01-08 |
Nagoya Institute Of Technology |
５’−ヒドロキシサリドマイド誘導体及びその製造方法
|
|
WO2009073146A2
(en)
|
2007-11-29 |
2009-06-11 |
Celgene Corporation |
Use of immunomodulatory compounds for the treatment of transverse myelitis, multiple sclerosis, and other disorders
|
|
WO2009085234A2
(en)
|
2007-12-20 |
2009-07-09 |
Signal Pharmaceuticals, Inc. |
Use of micro-rna as a biomarker of immunomodulatory drug activity
|
|
US20100098657A1
(en)
|
2007-12-27 |
2010-04-22 |
Schafer Peter H |
Method of Treating Cancer with Immunomodulatory Compounds and IgG
|
|
US20090171093A1
(en)
|
2007-12-28 |
2009-07-02 |
Yoshio Takeuchi |
3'-Fluoro-5'-hydroxythalidomide and derivatives thereof
|
|
WO2009105256A2
(en)
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
|
JP2009215195A
(ja)
|
2008-03-10 |
2009-09-24 |
Nagoya Institute Of Technology |
５’−フルオロサリドマイド誘導体及びその製造方法
|
|
JP5561577B2
(ja)
|
2009-07-01 |
2014-07-30 |
国立大学法人 名古屋工業大学 |
光学活性３’−フルオロサリドマイド誘導体の製造方法
|
|
CA2774871C
(en)
|
2009-10-20 |
2018-05-29 |
Tokyo Institute Of Technology |
Screening method utilizing thalidomide-targeting factor
|
|
WO2011160042A2
(en)
|
2010-06-18 |
2011-12-22 |
Makoto Life Sciences, Inc. |
Prpk-tprkb modulators and uses thereof
|
|
WO2012027065A2
(en)
|
2010-08-27 |
2012-03-01 |
Celgene Corporation |
Combination therapy for treatment of disease
|
|
EP2699091B1
(en)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
US8927725B2
(en)
|
2011-12-02 |
2015-01-06 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Thio compounds
|
|
WO2014180882A2
(en)
|
2013-05-07 |
2014-11-13 |
Universitat De Barcelona |
Treatment of brain metastasis from cancer
|
|
WO2015107196A1
(en)
|
2014-01-20 |
2015-07-23 |
Institut Curie |
Use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
US9931332B2
(en)
|
2014-07-30 |
2018-04-03 |
University Of Southern California |
Compositions and methods for treating primary effusion lymphoma
|
|
NZ731789A
(en)
*
|
2014-10-30 |
2019-04-26 |
Kangpu Biopharmaceuticals Ltd |
Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof
|
|
WO2016105518A1
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
SG11201708303XA
(en)
*
|
2015-05-22 |
2017-11-29 |
Biotheryx Inc |
Compounds targeting proteins, compositions, methods, and uses thereof
|
|
WO2017007612A1
(en)
|
2015-07-07 |
2017-01-12 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024317A2
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
WO2017024318A1
(en)
|
2015-08-06 |
2017-02-09 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
|
|
WO2017117474A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional compounds for her3 degradation and methods of use
|
|
WO2017117473A1
(en)
|
2015-12-30 |
2017-07-06 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molescules for her3 degradation and methods of use
|
|
BR112018068906A2
(pt)
|
2016-03-16 |
2019-01-22 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
|
|
US10759808B2
(en)
*
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
SG11201808728QA
(en)
|
2016-04-06 |
2018-11-29 |
Univ Michigan Regents |
Mdm2 protein degraders
|
|
US10696635B2
(en)
|
2016-04-18 |
2020-06-30 |
The Scripps Research Institute |
Versatile ligand for palladium-catalyzed meta-C—H functionalizations of aromatic substrates
|
|
EP3445765A4
(en)
|
2016-04-22 |
2019-09-18 |
Dana Farber Cancer Institute, Inc. |
DECREASE OF CYCLINE-DEPENDENT KINASE 4/6 (CDK4 / 6) BY CONJUGATION OF CDK4 / 6 INHIBITORS WITH E3-LIGASE LIGANDS AND METHODS OF USE
|
|
CA3018429A1
(en)
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 9 (cdk9) by conjugation of cdk9 inhibitors with e3 ligase ligand and methods of use
|
|
US10865205B2
(en)
|
2016-04-22 |
2020-12-15 |
Dana-Farber Cancer Institute, Inc. |
Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use
|
|
AU2017254713C1
(en)
|
2016-04-22 |
2021-04-29 |
Dana-Farber Cancer Institute, Inc. |
Bifunctional molecules for degradation of EGFR and methods of use
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
CN109790143A
(zh)
*
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
EP3454856B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
WO2017197056A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Bromodomain targeting degronimers for target protein degradation
|
|
WO2017201069A1
(en)
*
|
2016-05-18 |
2017-11-23 |
Biotheryx, Inc. |
Oxoindoline derivatives as protein function modulators
|
|
WO2017223452A1
(en)
|
2016-06-23 |
2017-12-28 |
Dana-Farber Cancer Institute, Inc. |
Degradation of bromodomain-containing protein 9 (brd9) by conjugation of brd9 inhibitors with e3 ligase ligand and methods of use
|
|
WO2017223415A1
(en)
|
2016-06-23 |
2017-12-28 |
Dana-Farber Cancer Institute, Inc. |
Degradation of tripartite motif-containing protein 24 (trim24) by conjugation of trim24 inhibitors with e3 ligase ligand and methods of use
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
CA3036834A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-oxazepines as bet protein degraders
|
|
CA3036841A1
(en)
|
2016-09-13 |
2018-03-22 |
The Regents Of The University Of Michigan |
Fused 1,4-diazepines as bet protein degraders
|
|
WO2018064589A1
(en)
|
2016-09-29 |
2018-04-05 |
Dana-Farber Cancer Institute, Inc. |
Targeted protein degradation using a mutant e3 ubiquitin ligase
|
|
CN110506039A
(zh)
*
|
2016-10-11 |
2019-11-26 |
阿尔维纳斯股份有限公司 |
用于雄激素受体靶向降解的化合物和方法
|
|
CN107056772A
(zh)
|
2017-01-23 |
2017-08-18 |
中国药科大学 |
基于cereblon配体诱导BET降解的双功能分子及其制备和应用
|
|
CN107698575A
(zh)
|
2017-09-26 |
2018-02-16 |
中国药科大学 |
cereblon配体介导的新型BET蛋白降解的双功能分子及其制备和应用
|
|
CN107739389B
(zh)
|
2017-11-03 |
2020-03-31 |
华东师范大学 |
3位取代的(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮类化合物及其合成方法
|
|
WO2019173224A1
(en)
*
|
2018-03-05 |
2019-09-12 |
Biotheryx, Inc. |
Deuterated compounds and chimeras and uses thereof
|
|
CA3106239A1
(en)
*
|
2018-07-27 |
2020-01-30 |
Biotheryx, Inc. |
Bifunctional compounds as cdk modulators
|
|
WO2020102195A1
(en)
*
|
2018-11-13 |
2020-05-22 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
WO2020118098A1
(en)
|
2018-12-05 |
2020-06-11 |
Vividion Therapeutics, Inc. |
Substituted isoindolinones as modulators of cereblon-mediated neo-substrate recruitment
|